XOMA Earns $25 Million Milestone Payment as Anti-TGFβ Antibody Enters Phase 2 Clinical Study in Metastatic Pancreatic Cancer Oct 28, 2020 7:30am EDT
XOMA Reports First Quarter 2020 Financial Results and Provides COVID-19 Business Update May 05, 2020 7:30am EDT
XOMA Reports Fourth Quarter and Full-Year 2019 Financial Results and Operating Highlights Mar 10, 2020 7:30am EDT
Zydus and XOMA Announce IL-2-Based Immuno-Oncology Therapy Licensing Agreement Mar 09, 2020 5:00am EDT
